Mobile

A trial to evaluate the pharmacokinetics, safety, and tolerability of MK-7655A in children less than 18 years old with confirmed or suspected gram-negative infections

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-004328-43

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To obtain plasma PK data and characterize the PK profile of imipenem, cilastatin, and relebactam (REL) following administration of a single IV dose of IMI/REL in pediatric subjects from birth to less than 18 years of age receiving standard-of-care antibacterial therapy for a confirmed or suspected Gram-negative bacterial infection.

Critère d'inclusion

  • Treatment of bacterial infections in pediatric populations

Liens